Performance of shear-waves elastography in the non-invasive assessment of liver fibrosis in chronic hepatitis in the Romanian population

Abstract

Background: Liver fibrosis is one of the major factors associated with progression of liver disease in chronic HBV [1] or HCV [2,3] infection, but also in metabolic diseases with impact on the liver. Methods: We have performed a study to determine liver stiffness in patients with chronic hepatitis in Romania. One trained operator performed shear-waves elastography (SWE) using Aixplorer (SuperSonic Imagine, Aix-en-Provence, France) in all consecutive patients monitored in our clinic over the course of 7 months, from January 2014 to July 2014. Results: We have examined a total of 80 patients with chronic hepatitis, of which 58.8% had HCV infection, 16.3% HBV infection, 6.3% HBV+HDV coinfection, 2.5% ASH, 2.5% HIV infection and 13.8% had idiopathic liver involvement. The male-to-female ratio was 0.86:1, and the mean age was 48.6+/-14.9 years. The mean duration of hepatic disease evolution was 7.6+/-5.7 years, longer for HCV infection (mean 8.3+/-5.9 years) than for HBV infection (4.75+/-3.9 years, p=0.028). The overall mean SWE liver stiffness was 9.6+/-5.3 kPa, higher in patients with HCV infection (10.8+/-5.9 kPa) than in those with HBV infection (6.98+/-1.9 kPa, p=0.009). Overall, 37.5% of patients were classified as F0-F1 on SWE, 25.0% F2, 8.8% F3 and 28.7% F4. Liver cirrhosis was present in 28.7% of patients and hepatocellular carcinoma had already been diagnosed in 6.3% of all patients and in 21.7% of all patients with cirrhosis (5 cases, of which 4 had been previously diagnosed with cirrhosis with HCV - 3 cases, and HBV+HDV -1 case, and 1 had an idiopathic cause for liver involvement and a stiffness corresponding to F0-F1 on SWE). Conclusion: There seem to be significant differences between two of the main groups of patients examined, with a longer duration of infection and an accordingly higher liver stiffness in the chronic HCV group, when compared to the chronic HBV group.